Core Viewpoint - The controversy surrounding the store "胖都来" highlights a troubling trend where businesses attempt to exploit the reputation of established brands like "胖东来" instead of focusing on genuine product and service quality [2][3]. Group 1: Brand Protection and Market Regulation - The emergence of similar names such as "胖西来", "胖南来", and "胖北来" reflects a lack of effective market regulation, allowing opportunistic businesses to thrive at the expense of established brands [2]. - The current regulatory framework, including the "Enterprise Name Registration Management Regulations", emphasizes the protection of legitimate business rights and the maintenance of economic order, but enforcement is lacking [2][5]. - There are significant challenges for companies seeking to protect their intellectual property, including lengthy legal processes and high costs that may outweigh potential compensation [2]. Group 2: Call for Action and Improvement - There is a pressing need for local market regulatory bodies to take proactive measures to foster a better business environment and protect well-known brands from imitation [3][5]. - The upcoming "China Brand Day" and the implementation of the Private Economy Promotion Law present opportunities for enhancing brand protection and promoting high-quality economic development [5]. - A unified approach among various departments is essential to support brand economy growth and to establish a culture of innovation and practical action within society [5].

据了解，此次地方分中心的增设，旨在加强企业海外知识产权纠纷应对指导，更好服务区域经济发展。 河南省知识产权维权保护中心积极响应，广泛动员、组织指导条件成熟的地方申报。漯河市、南阳市、 周口市知识产权维权保护中心以扎实的工作基础与专业的业务能力，经国家知识产权局初评打分、专家 评审等程序，最终脱颖而出，获批成立。 新设的3家地方分中心成立后，将深度配合国家海外知识产权纠纷应对指导中心，着力构建资源共享、 信息报送、协调联动和培训指导工作机制，承担海外知识产权信息的收集与报送、海外知识产权纠纷应 对的咨询与指导等工作，同时结合本地产业特色，探索创新业务运行模式，切实提升各类社会主体海外 知识产权保护意识与应对能力。 5月8日，记者获悉，国家知识产权局日前公布第五批海外知识产权纠纷应对指导中心地方分中心（简 称"地方分中心"）名单，我省漯河市、南阳市、周口市知识产权维权保护中心成功入选。至此，全省地 方分中心增至5家，海外知识产权纠纷应对指导体系建设迈出坚实步伐，为护航河南企业"走出去"注入 新动能。 下一步，省知识产权维权保护中心将继续聚焦"四高四争先"，围绕重点产业链群建设、深化制度型开放 等重大举措，持续推进 ...

康希通信 20250508 摘要 • 康希通信凭借 Wifi 7 技术先发优势，与博通等国际主流 SoC 厂商达成合作， 产品进入其参考设计平台，为扩大国际市场份额奠定基础。2025 年第一 季度营收达 1.35 亿元，同比增长 64.53%，Wifi 7 产品销量是核心驱动 力。 • 公司积极拓展多元化产品线，包括低空经济（大功率无线通讯）、工业物 联网（星闪射频前端）、车联网 V2X 等领域，并已取得初步进展，有望成 为新的增长点。2024 年研发投入 1.08 亿元，同比增长 71%。 • 面对 Skyworks 的专利诉讼和 337 调查，康希通信积极应诉，已成功撤回 3 项涉诉专利，并深化全球专利布局，构建知识产权保护网，维护自主研 发成果。预计 2025 年年中正式开庭。 • 公司通过分阶段回购股份，累计斥资超 8,000 万元，传递价值认同，强化 市值管理，维护股东权益。同时，实施股权激励和员工持股计划，绑定核 心团队，实现市值与内在价值良性互动。 • 公司战略聚焦 Wi-Fi 产品护城河构建、多元化产品布局、知识产权保卫战 和强化市值管理。积极参与 Wi-Fi 8 技术探索，并加强参投企业协同 ...

众生药业（002317）公告，控股子公司众生睿创收到日本特许厅颁发的专利证书，专利名称为"ポリペ プチドの調製およびその使用"，专利号为7672503，专利申请日为2022年05月30日，专利权人为众生睿 创，专利权期限为自申请日起二十年。该专利为RAY1225项目的化合物专利，属于该项目的核心专 利。RAY1225注射液是一款具有GLP-1受体和GIP受体双重激动活性的多肽药物，目前处于III期临床试 验阶段。此次专利授权有利于公司进一步完善知识产权保护体系，发挥自主知识产权优势，但不会对公 司短期的财务状况、经营业绩构成重大影响。 ...

近期，我市知识产权部门将对接市贸促会，进驻大型展会、赛事，通过"线上+线下"相结合的方 式，指导参展商对其参展产品和宣传材料进行自查，预防海外侵权纠纷。同时，围绕我市"876"创新引 领工程，开展知识产权布局和预警，鼓励支持企业通过自主申请、许可和收购等方式，获取高质量的海 外知识产权。（记者 朱婕 通讯员 金瑞） 近日，我市知识产权保护中心获批设立国家级海外知识产权纠纷应对指导地方分中心，标志着我市 知识产权保护工作再度"升级"，护航企业"出海"将更有底气和保障。 此次案件中，市知识产权保护中心联合海外知识产权纠纷应对指导扬州分中心开展线上指导培训， 结合案件开展案情回顾和风险预判，向涉案企业介绍相关风险应对策略，提供指导意见。 近年来，我市外向型经济持续推进，进出口规模屡创新高。今年一季度，全市进出口总值254.1亿 元、同比增长6.5%，首次实现一季度进出口总值突破250亿元大关。随着企业"走出去"步伐不断加快， 海外知识产权纠纷也日益增多。对此，市知识产权保护中心通过多方联动、建立海外纠纷应对协作等机 制全力护航"出海"，2023年至今累计监测、跟踪我市企业海外知识产权纠纷案件80余起。 "实践表明， ...

浙江省东阳市公安局在网络巡查中发现，某影视网站上出现了《哪吒之魔童闹海》《唐探1900》《封神 第二部：战火西岐》等春节档热门电影。 刚刚上映不到3天的电影，怎么会出现在网络上？当地公安机关马上意识到，这可能涉及一起影视作品 盗版侵权案。 是谁在幕后操控这一切？带着疑惑，东阳公安立即成立专案组，迅速开展线索核查。 重要线索浮出水面 然而，令他没有想到的是，他盗拍的片源已在多个非法网站上被无数次点击观看。 警方很快锁定侵权网站经营者任某，在他的电子设备中找到大量盗录视频，并在服务器上发现30多个视 频网站。 网络上传播的盗版春节档热门电影，往往是从电影院盗录获得，也就是俗称的"枪版"。 经过全网排查，警方发现春节档的热门电影之一《哪吒之魔童闹海》于1月29日上映，上映第二天11时 左右即出现全片盗录资源。 公安机关迅速展开调查，很快确定华南某省的某家影院是盗录地点之一。排查场次、查看监控，警方马 上锁定了盗录影片的犯罪嫌疑人江素（化名）。 确定了盗版源头，专案组立即开始向下追踪，打击传播盗版影视作品的网站经营者，截断网络传播的渠 道。 抽丝剥茧，层层推进，案情逐渐明朗。一头找到盗录影片的源头，一头控制住网站的实 ...

Cerence (CRNC) Q2 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Hello, everyone, and welcome to Cerence's second quarter twenty twenty five conference call. I'm Kate Hickman, VP of corporate communications and investor relations. I've been with the company for nearly eight years leading communications, and I'm excited to now be leading Investor Relations as well. I look forward to getting to know all of you. Before we begin, I would like to remind you that this call may involve certain forward lookin ...

【深圳商报讯】（记者李佳佳）日前，记者从深圳市市场监督管理局（知识产权局）获悉，深圳获国家 知识产权局批复，同意深圳市福田区开展国家级知识产权快速维权中心建设。 据透露，这是我市首家获批建设的国家级知识产权快速维权中心，按照相关要求完成建设任务并验收合 格后，将纳入全国知识产权快速协同保护工作机制，面向时尚设计产业开展知识产权快速维权工作。 深圳一直以来把知识产权作为创新驱动发展和优化营商环境的重要支撑，持续深化知识产权领域改革创 新，深入开展知识产权体系建设，在国家知识产权强市建设示范城市、国家知识产权保护高地"双示 范"建设中迈出坚实步伐。 知识产权保护中心和快速维权中心是国家知识产权保护体系的两大组成部分，是服务创新主体、优化营 商环境的重要力量。国家级知识产权快速维权中心聚焦外观设计、工业设计领域对于知识产权快速保护 的迫切需求，在相关产业优势聚集的地区重点开展知识产权快速确权、快速授权、快速维权等服务。 据了解，深圳福田（时尚设计）快维中心建成后，将使时尚设计相关产业外观设计专利授权时间大幅缩 短80%以上（外观设计专利授权时限最快1周），从"被动防御"到"主动护航"，通过打通绿色授权、维 权快车道 ...

Avadel Pharmaceuticals (AVDL) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Austin Murtagh - Director of Investor Relations & External CommunicationsGregory Divis - CEOThomas McHugh - CFOAndrew Tsai - SVPMarc Goodman - Senior MD - NeuroscienceDi Zhao - Equity Research Associate - Biopharmaceuticals/Biotechnology Conference Call Participants David Amsellem - Sr. Research AnalystDavid Hoang - Director, Senior Analyst, BiotechnologyMyriam Belghiti - Equity Research AnalystAmi Fadia - Seni ...

Financial Data and Key Metrics Changes - The company reported net revenue of $52.5 million for Q1 2025, representing over 90% growth compared to Q1 2024, which had net revenue of $27.2 million [7][18] - Gross profit for Q1 2025 was $46.9 million, up from $25.7 million in the prior year [18] - The company raised its full-year revenue guidance to $255 million to $265 million from a previous range of $240 million to $260 million [17][19] Business Line Data and Key Metrics Changes - The company ended Q1 with 2,800 patients on LUMRIZE, reflecting 100% growth year-over-year [6] - There was a 50% increase in net new patients during Q1 compared to Q4 2024, with an addition of 300 patients [6] - The company expanded its sales force by 15% and doubled the size of its field reimbursement and nursing support teams, contributing to improved patient engagement and persistency [8][9][10] Market Data and Key Metrics Changes - The company is pursuing additional indications for LUMRIZE beyond narcolepsy, particularly idiopathic hypersomnia (IH), with an estimated 42,000 patients diagnosed and only one FDA-approved treatment currently available [11][12] - The company believes LUMRIZE has the potential to unlock significant market opportunities in IH, as prescribers express excitement about the prospect of prescribing it for this condition [11][12] Company Strategy and Development Direction - The company aims to achieve $1 billion in LUMRIZE revenue while expanding its impact to additional patient populations [15] - The company is focused on lifecycle management initiatives to maximize the potential of its once-at-bedtime formulation beyond narcolepsy [23] - The company is actively pursuing legal actions to protect its intellectual property and has a robust portfolio that extends protection until 2042 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial investments made at the beginning of the year, which are expected to drive sustainable positive cash flow [23] - The company remains optimistic about its growth trajectory, despite potential industry-wide changes related to tariffs and policies impacting biotech [21] - Management highlighted the importance of maintaining financial discipline while scaling operations and expects continued revenue growth and cash flow improvement [19][20] Other Important Information - The company ended Q1 2025 with $66.5 million in cash, cash equivalents, and marketable securities [20] - The company reported a GAAP operating loss of $3 million for Q1, but adjusted operating income was positive at $2 million, marking the third consecutive quarter of positive adjusted operating income [20] Q&A Session Summary Question: Revised 2025 guidance and growth assumptions - Management confirmed that the first half of the year is expected to show sequential growth quarter over quarter, with a focus on improving key metrics [28][29] Question: Nature of the recent court ruling - Management indicated that the ruling was aligned with their base case scenario and provides a clear path to continue executing their plans for LUMRIZE [34][35] Question: Patient metrics and competitive landscape for IH - Management views the IH opportunity as highly untapped and believes LUMRIZE can successfully source patients from various segments, including those not currently treated with oxybate [40][41] Question: Discontinuation rates and updated guidance - Management reported a decrease in discontinuation rates from 14% in Q4 to a lower figure in Q1, contributing to increased confidence in their updated guidance [77][79] Question: Offensive lawsuits and timelines - Management elaborated on their offensive lawsuits against Jazz, asserting their intellectual property rights, and mentioned upcoming administrative steps in the litigation process [81][84]